From August 24, 2023 to September 30, 2023, the company has repurchased 533,100 shares, representing 0.49% for CNY 34.05 million. With this, the company has completed the repurchase of 533,100 shares, representing 0.49% for CNY 34.05 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
63.73 CNY | +5.03% |
|
+5.41% | -2.10% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.10% | 949M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.